… -directed therapy over the following years. Here, we will review these recent … ErbB-directed
therapies. Although we will focus on the mechanisms of action of ErbB therapeutic antibodies, …

… For this reason ErbB receptors are attractive therapeutic targets and many different …
Recombinant antibody toxins have been derived which target different members of the ErbB receptor …

… to lysosomal degradation following ligand-induced receptor internalization, whereas the
other erbB receptors are relatively endocytosis impaired and tend to be recycled back to the cell …

… antibodies have been the focus of intense development as anti-cancer agents. In this review
we consider the properties of ErbB receptors antibodies … to be of therapeutic value remains …

… antibodies generated against the receptor's ligand-binding extracellular domain. These
antibodies block the binding of receptor-… , can induce receptor endocytosis and downregulation. …

… the ErbB family of tyrosine kinase receptors in cancer therapy. In particular, preliminary results
will be discussed of studies of the first generation of therapeutics … factor receptor antibody …

… These include mAbs against the receptors for epidermal growth factor (EGF), HER-2 (c-erbB-2/neu),
transferrin, insulin-like growth factor, interleukin-1, and interleukin-2. Some well-…

… or therapeutic antibodies. In addition to trastuzumab, the first humanized antibody that was
approved for the therapy … preferred heterodimerization partner of all ErbB receptors, and it can …

… Although antibodies derived for the oncogenic rat receptor established the principle of
rational, targeted disabling of oncoproteins and bound to an epitope shared by human p185 her2/…

… therapeutic antibodies that target the same receptor. The plethora of structural studies on ErbB
receptors … how ErbB receptors are likely to dimerize and why it might be better to have two …